Redhill Biopharma Ltd., of Tel Aviv, Israel, said it concluded a type B meeting with the FDA on its chemistry, manufacturing and controls aspect of the RBH-105 phase III program. Subject to final minutes of the meeting, the FDA accepted the firm's manufacturing plan for an NDA to be submitted for the fixed-dose, oral combination therapy for the eradication of H. pylori infection, subject to positive results from the planned confirmatory phase III study.